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Abstract
Background
Dolutegravir (DTG)–based dual therapy is becoming a new paradigm for both the initiation
and maintenance of HIV treatment. The SIMPL’HIV study investigated the outcomes of viro-
logically suppressed patients on standard combination antiretroviral therapy (cART) switch-
ing to DTG + emtricitabine (FTC). We present the 48-week efficacy and safety data on
DTG + FTC versus cART.
Methods and findings
SIMPL’HIV was a multicenter, open-label, non-inferiority randomized trial with a factorial
design among treatment-experienced people with HIV in Switzerland. Participants were
enrolled between 12 May 2017 and 30 May 2018. Patients virologically suppressed for at
least 24 weeks on standard cART were randomized 1:1 to switching to DTG + FTC or to
continuing cART, and 1:1 to simplified patient-centered monitoring versus standard
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monitoring. The primary endpoint was the proportion of patients virologically suppressed
with <100 copies/ml through 48 weeks. The secondary endpoints included virological
suppression at 48 weeks according to the US Food and Drug Administration (FDA) snap-
shot analysis. Non-inferiority of DTG + FTC versus cART for viral suppression was
assessed using a stratified Mantel–Haenszel risk difference, with non-inferiority declared
if the lower bound of the 95% confidence interval was greater than −12%. Adverse events
were monitored to assess safety. Quality of life was evaluated using the PROQOL-HIV
questionnaire. Ninety-three participants were randomized to DTG + FTC, and 94 individ-
uals to cART. Median nadir CD4 count was 246 cells/mm3; median age was 48 years;
17% of participants were female. DTG + FTC was non-inferior to cART. The proportion of
patients with viral suppression (<100 copies/ml) through 48 weeks was 93.5% in the
DTG + FTC arm and 94.7% in the cART arm in the intention-to-treat population (risk dif-
ference −1.2%; 95% CI −7.8% to 5.6%). Per-protocol analysis showed similar results,
with viral suppression in 96.5% of patients in both arms (risk difference 0.0%; 95%
CI −5.6% to 5.5%). There was no relevant interaction between the type of treatment and
monitoring (interaction ratio 0.98; 95% CI 0.85 to 1.13; p = 0.81). Using the FDA snapshot
algorithm, 84/93 (90.3%) participants in the DTG + FTC arm had an HIV-1 RNA viral load
of <50 copies/ml compared to 86/94 (91.5%) participants on standard cART (risk differ-
ence −1.1%; 95% CI −9.3% to 7.1%; p = 0.791). The overall proportion of patients with
adverse events and discontinuations did not differ by randomization arm. The proportion
of patients with serious adverse events was higher in the cART arm (16%) compared to
the DTG + FTC arm (6.5%) (p = 0.041), but none was considered to be related to the
study medication. Quality of life improved more between baseline and week 48 in the
DTG + FTC compared to the cART arm (adjusted difference +2.6; 95% CI +0.4 to +4.7).
The study’s main limitations included a rather small proportion of women included, the
open label design, and its short duration.
Conclusions
In this study, DTG + FTC as maintenance therapy was non-inferior to cART in terms of effi-
cacy, with a similar safety profile and a greater improvement in quality of life, thus expanding
the offer of 2-drug simplification options among virologically suppressed individuals.
Trial registration
ClinicalTrials.gov NCT03160105.
Author summary
Why was the study done?
• Treatment simplification among people with HIV has been tested worldwide and
includes reducing the number and/or dosage of antiretroviral drugs, and simplifying
monitoring, but without compromising adherence and quality of life.
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• We evaluated the combination of dolutegravir (DTG) + emtricitabine (FTC) as an alter-
native to standard therapy combinations in an HIV population highly representative of
routine clinical conditions.
• Simplified patient-centered monitoring was also evaluated, to allow patients to receive
care outside the hospital as is usual in Switzerland.
What did the researchers do and find?
• We conducted the SIMPL’HIV study, a randomized trial with a factorial design, to per-
mit patients with a suppressed viral load to receive a simplified treatment of DTG +
FTC and/or simplified patient-centered monitoring.
• Efficacy of the DTG + FTC regimen was defined as keeping the patient’s HIV viral load
below 100 copies/ml through 48 weeks of study duration.
• The combination of DTG with FTC had a similar efficacy in maintaining viral suppres-
sion through 48 weeks of treatment as standard combined antiretroviral therapy, with-
out jeopardizing safety, and it improved patient quality of life.
What do these findings mean?
• These results provide further evidence on the efficacy of 2-drug DTG-based regimens as
a simplified switch option for patients whose viral load is well controlled on standard
treatment, including those with a low CD4 nadir, and expands the currently existing
options for dual maintenance therapy.
• Our efficacy definition allowed us to observe the occurrence of HIV viral load blips,
irrespective of the treatment arm, without any consequences for HIV management.
• The quality of life of the participants was already very satisfactory at the start of the
study and further increased over time with the simplified DTG + FTC treatment.
Introduction
Treatment optimization has been at the forefront of innovative HIV-1 care management.
Dual-therapy regimens are already considered appropriate alternatives to standard combina-
tion antiretroviral therapy (cART) as they have been approved by the US Food and Drug
Administration (FDA) and the European AIDS Clinical Society (EACS) guidelines for both
initial and maintenance therapy [1,2].
Dual therapy may also be associated with reduced toxicity and costs and improved tolera-
bility, adherence, and quality of life (QoL) [3].
In recent years, there has been a focus on dolutegravir (DTG)–based simplification ther-
apy. DTG is a potent second-generation integrase strand transfer inhibitor (InSTI) with a
high genetic barrier to resistance, rare severe side effects, and very few drug–drug interac-
tions [4]. While DTG is associated with a substantial risk of virological failure in maintenance
monotherapy [5,6], it remains a good candidate for dual therapy. The GEMINI phase III tri-
als established the non-inferiority and tolerability of DTG plus lamivudine (3TC) in
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Abbreviations: 3TC, lamivudine; cART,
combination antiretroviral therapy; DTG,
dolutegravir; EACS, European AIDS Clinical Society;
FDA, US Food and Drug Administration; FTC,
emtricitabine; InSTI, integrase strand transfer
inhibitor; ITT, intention-to-treat; NRTI, nucleoside
reverse transcriptase inhibitor; PCM, patient-
centered monitoring; PP, per protocol; PWHIV,
people with HIV; QoL, quality of life; SHCS, Swiss
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ART-naïve patients [7]. In selected patients, the TANGO study demonstrated the non-inferi-
ority and safety of DTG plus 3TC in maintenance therapy versus a standard cART containing
tenofovir alafenamide [8]. In heavily treatment-experienced patients and in the presence of
historical 3TC resistance, the dual regimen DTG + 3TC allowed maintenance of virological
suppression at week 48, as shown by the DOLULAM and ART-PRO pilot clinical trials
[9,10].
We aimed to investigate the efficacy and safety of DTG plus emtricitabine (FTC) dual
therapy, which has not yet been examined to our knowledge. FTC is similar to 3TC with
respect to the convenience, safety, and resistance profile, but it has a longer intracellular half-
life activity and shows greater in vitro potency, results that contributed to the selection of
FTC for subsequently developed triple antiretroviral fixed dose combinations [11]. We aimed
to examine the efficacy and safety of DTG + FTC dual therapy in a nationally representative
sample of people with HIV (PWHIV) that included a substantial percentage of women. We
did not use any CD4 nadir or HIV-1 RNA zenith restrictions, thus mirroring routine care
while reducing the number of drugs and costs to the health system. Finally, no trial to our
knowledge has simultaneously explored the non-inferiority of dual therapy and of simplified
and individualized patient-centered treatment monitoring, which was made possible by a fac-
torial study design.
SIMPL’HIV was a multicenter, non-inferiority, open-label, randomized, factorial trial con-
ducted in Switzerland. The primary objective of SIMPL’HIV was to assess the 48-week efficacy
and safety of DTG + FTC dual maintenance therapy in virologically suppressed PWHIV com-
pared with standard cART. As a co-primary objective, the study aimed to compare a patient-
centered monitoring (PCM) approach with standard 3-monthly routine surveillance (standard
monitoring [SM]). Here we focus on the comparison between DTG + FTC and cART in terms
of efficacy, safety, and QoL; costs and other outcomes for the comparison of the monitoring
options are not reported in this paper.
Methods
Design and participants
SIMPL’HIV was performed in the 7 main Swiss HIV Cohort Study (SHCS) sites [12] with par-
ticipants enrolled between 12 May 2017 and 30 May 2018. The week 48 database was frozen on
3 July 2019. The study, with an open-label design, recruited PWHIV aged 18 years or over and
already enrolled in the SHCS network. Patients were eligible if they were on any EACS-recom-
mended cART [13] and virologically suppressed for at least 24 weeks prior to enrollment, with
virological suppression defined as HIV-1 RNA < 50 copies/ml, although we allowed a single
blip of<200 copies/ml in the past 6 months. We excluded patients who had previous treat-
ment change due to an unsatisfactory virological response such as slow initial or incomplete
virological suppression or rebound. Patients with only a transmitted M184V mutation became
eligible from 27 June 2017, following a protocol amendment, in an effort to include individuals
with transmitted nucleoside reverse transcriptase inhibitor (NRTI)–selected mutations. Exclu-
sion criteria included the following: presence of InSTI resistance mutations according to the
French National Agency for AIDS Research version 29 algorithm [14], pregnant or breastfeed-
ing women, HIV-2 infection, creatinine clearance of<50 ml/min, transaminase elevation>2.5
times the upper limit of the norm, known hypersensitivity to DTG or FTC, known or sus-
pected non-adherence to current treatment, and evidence of acute or chronic hepatitis B virus
infection. Written informed consent was obtained from each participant before the initiation
of study procedures.
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Randomization
Participants were randomly assigned 1:1 to switch to DTG + FTC dual maintenance therapy
or continue their cART, and 1:1 to PCM or SM (S1 Fig). An independent statistician generated
a computer-based random allocation sequence stratified by study site, using randomly permu-
tated blocks of size 4 and 8 to randomize patients to the 4 arms. The randomization list was
implemented by an independent data manager in a web-based data management system in
order to ensure concealment of allocation.
Procedures
Patients were randomized to receive a once-daily 2-drug regimen of DTG 50 mg plus FTC 200
mg or to continue their standard cART, as well as to PCM or SM. Allocation to SM consisted
of 3-monthly routine immunological and blood safety tests including CD4 cell count, lipid
profile, glucose level, renal and hepatic function tests, and creatinine kinase, with all visits and
laboratory analyses conducted at the affiliated SHCS sites. Participants allocated to the PCM
arm had a restricted immunological and blood safety monitoring at weeks 0 and 48. In addi-
tion, participants were offered the choice to complete some of the study visits by a telephone
call with a study nurse, to have their drugs delivered to a specified address, or to have their
blood tests performed at alternative locations, including certified private laboratories.
All participants had HIV-1 RNA measurements performed at all study visits, which were
scheduled every 6 weeks between baseline and week 12, and every 12 weeks thereafter until the
study ended. We quantified HIV-1 RNA levels using PCR assays with a limit of detection of 20
copies/ml or less at local virology laboratories. Patients with HIV-1 RNA between 20 and 99
copies/ml were retested after 6 weeks (±5 days). Patients with HIV-1 RNA� 100 copies/ml
were retested after 14 days (±5 days), received additional adherence sessions, had their concom-
itant medications reviewed, and had drug plasma concentration measurements performed. In
patients with virological failure, defined as 2 consecutive plasma HIV-1 RNA values� 100 cop-
ies/ml, genotypic resistance testing was performed as part of routine care by 4 laboratories in
Switzerland authorized by the Federal Office of Public Health. All laboratories performed popu-
lation-based sequencing. Drug resistance was defined using the French National Agency for
AIDS Research version 29 algorithm [14]. If randomized to the DTG +FTC dual therapy arm,
patients were switched to a standard cART regimen while awaiting results of genotypic resis-
tance testing. Patients in the control arm remained on their cART regimen while awaiting the
genotypic results. Treatment was adjusted in both cases according to genotypic resistance
results. We quantified the plasma levels of DTG and FTC by liquid chromatography coupled to
tandem mass spectrometry in the Laboratory of Clinical Pharmacology at Lausanne University
Hospital at week 48, using adaptations of previously published methods [15–17].
We recorded adverse events, concomitant medications, and adherence checks and per-
formed symptom-directed physical examinations at all study visits. We graded adverse events
by severity on a scale from 1 to 4 using the categories in the International Council for Harmo-
nisation of Technical Requirements for Registration of Pharmaceuticals for Human Use E2A
guidelines [18]. Serious adverse events were defined according to the same guidelines. Urinary
pregnancy testing was done at the screening visit and every 6 months thereafter (i.e., at week
24 and 48 visits) for women of childbearing age.
Outcomes
The primary outcome for the comparison between DTG + FTC and cART was the mainte-
nance of HIV-1 RNA < 100 copies/ml through the 48-week duration of the study. A single
blip, defined as HIV-1 RNA between 100 and 199 copies/ml at any time during the study
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period, was allowed as long as this measurement was followed by an HIV-1 RNA result of<50
copies/ml. Secondary endpoints included the proportion of patients with HIV-1 RNA < 50
copies/ml at week 48 according to the FDA snapshot algorithm [19], the proportion with
HIV-1 RNA < 50 copies/ml through 48 weeks, the proportion experiencing loss of future drug
options and time to loss of virological response, changes in CD4 cell count, changes in HIV
DNA, adherence through the study, and changes in health-related QoL as assessed by the
PROQOL-HIV questionnaire [20,21] from baseline to week 48. We also assessed on which
drug regimen participants chose to stay at study termination. To be aligned with FDA guide-
lines, the protocol was amended on 30 July 2019 to increase the window for the FDA snapshot
analysis from 7 to 21 days.
Safety endpoints included the incidence, type, and seriousness of adverse events, as well as
the discontinuation of treatment. Renal function, lipids, Framingham cardiovascular risk
score, glucose, and weight were monitored by assessing changes from baseline to week 48.
The co-primary outcome, for the comparison between PSM and SM, was the direct costs
from the healthcare system perspective of the 2 monitoring options. Secondary outcomes for
the comparison of monitoring arms included cost-effectiveness; the number of extra visits dur-
ing the study period; in the PSM arm, participants’ monitoring satisfaction and the proportion
of participants expressing willingness to change monitoring options during the study; and all
participants’ satisfaction with treatment, monitoring, and study participation. Primary and
secondary outcomes related to the comparison of the monitoring options will not be presented
in this paper.
Sample size calculation and statistical analyses
We determined the target sample size for the non-inferiority comparison between DTG +FTC
and cART on the primary outcome, assuming that there was no interaction between the treat-
ment and monitoring strategy. The targeted sample size of 184 patients (allowing for at least
10% loss to follow-up) was based on 80% power, a 2.5% 1-sided alpha level, expected propor-
tions of HIV-1 RNA < 100 copies/ml through 48 weeks of 94% and 97% in the DTG + FTC
and cART arm, respectively, and a non-inferiority margin of −12%, as used in previous non-
inferiority HIV trials [22–29].
We primarily analyzed the trial as a stratified 2-arm trial comparing DTG + FTC with
cART, with monitoring type (PCM versus SM) being the stratification factor. The primary out-
come was assessed in both the intention-to-treat (ITT) and per-protocol (PP) populations, as
recommended by the FDA guidance for non-inferiority trials [30]. PP exclusion criteria
included missing HIV-1 RNA results at week 48 (±21-day window), unless virological failure
occurred before; treatment adherence< 80%; and any major protocol deviations. We assessed
interaction between the type of drug treatment and monitoring by calculating an interaction
ratio [31] and a p-value using the Mantel–Haenszel test of homogeneity in order to exclude
that the treatment effect on viral suppression was different depending on the type of
monitoring.
We summarized baseline characteristics and adverse events using descriptive statistics. We
evaluated the primary outcome using the Mantel–Haenszel risk difference stratified by the
monitoring type [32], declaring non-inferiority if the corresponding lower 95% confidence
limit was above the margin of −12%. We compared secondary binary outcomes using the
Cochran–Mantel–Haenszel test statistic and Mantel–Haenszel risk difference, stratified by the
type of monitoring. We analyzed continuous variables using linear regression adjusted for the
type of monitoring and the baseline value. All statistical analyses were performed with R soft-
ware, version 3.6.1 [33].
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An independent data monitoring committee reviewed descriptive safety data after the first
100 participants had completed the week 24 study visit. SIMPL’HIV is registered on Clinical-
Trials.gov (NCT03160105). This report was written according to the CONSORT statement for
non-inferiority trials; the CONSORT checklist is available in S1 Text [34].
Ethics statement
The study protocol was approved by both the leading and local ethics committees in Switzer-
land, in accordance with the Helsinki Declaration and good clinical practice. The full protocol
is available in S2 Text.
Results
Of 873 individuals screened for eligibility, 188 were randomly assigned either to switch to
DTG + FTC dual therapy or to continue their cART (Fig 1). One randomization occurred by
mistake (ineligible patient mistakenly randomized), leading to 93 participants allocated to
Fig 1. Overview of study flow chart. �Ineligible patient mistakenly randomized. cART, combination antiretroviral therapy; DTG,
dolutegravir; FTC, emtricitabine; InSTI, integrase strand transfer inhibitor; PCM, patient-centered monitoring; SAE, serious adverse
event; SM, standard monitoring; VF, virological failure.
https://doi.org/10.1371/journal.pmed.1003421.g001
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DTG + FTC dual therapy, with 48 participants in the PCM arm and 45 in the SM arm, and 94
participants allocated to continuing cART, with 47 in each of the monitoring arms. The num-
ber of participants who discontinued treatment before week 48 was similar between the 2 treat-
ment arms, 8 in each arm. Reasons for study discontinuation included premature stop or loss
to follow-up (n = 6), discontinuation due to an adverse event (n = 2), change to previous cART
for a reason other than virological failure (n = 1), and low adherence (n = 1).
Baseline characteristics
Key demographic and baseline characteristics were well balanced between the treatment arms
in the ITT population (Table 1). Participants were mostly white (79%), with a median age of
48 years (interquartile range [IQR] 40–54); 17% were female. The median CD4 nadir was 246
cells/mm3 (IQR 103–330) in the DTG + FTC arm, and 253 cells/mm3 (IQR 174–367) in the
cART arm. Standard cART at inclusion comprised an association of 2 NRTIs with an InSTI
for two-thirds of participants. DTG was the InSTI received before study entry for one-half of
all participants.
Primary outcome (efficacy)
DTG was non-inferior to cART in maintaining viral suppression; 87/93 (93.5%) participants
in the DTG + FTC dual therapy arm and 89/94 (94.7%) in the cART arm achieved HIV-1
Table 1. Demographic and clinical baseline characteristics of the intention-to-treat population.
Characteristic DTG + FTC
(n = 93)
cART
(n = 94)
Median age (years) [IQR] 48 [40–53] 47 [42–54]
Female, n (%) 14 (15) 18 (19)
Ethnicity, n (%)
White 73 (78.5) 75 (79.8)
Asian 2 (2.2) 3 (3.2)
Black 12 (12.9) 12 (12.8)
Other 6 (6.4) 4 (4.2)
Positive HCV serology, n (%) 8 (8.6) 9 (9.6)
Median CD4 baseline (cells/mm3) [IQR] 664 [515–898] 686 [497–847]
Median CD4 nadir (cells/mm3) [IQR] 246 [103–330] 253 [174–367]
Median viral load zenith (copies/ml) [IQR] 109,757 [41,200–326,000] 100,000 [31,000–303,000]
Median body mass index (kg/m2) [IQR] 25 [23–26] 25 [23–27]
Median time since ART initiation (years) [IQR] 7.9 [4.1–12] 7.1 [3.8–13]
Median time since HIV diagnosis (years) [IQR] 10 [5–15] 11 [6–17]
AIDS events during the last 5 years, n (%) 1 (1.1) 0
cART at inclusion, n (%)
2 NRTI + InSTI 59 (63.4) 62 (66.0)
2 NRTI + 1 NNRTI 27 (29.0) 24 (25.5)
2 NRTI + 1 boosted PI 5 (5.4) 6 (6.4)
Other 2 (2.2) 2 (2.1)
Documented M184V mutation, n (%) 0 1 (1.1)
AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; cART, combined antiretroviral therapy;
DTG, dolutegravir; FTC, emtricitabine; HCV, hepatitis C virus; HIV, human immunodeficiency virus; InSTI,
integrase strand transfer inhibitor; IQR, interquartile range; NNTRI, non-nucleoside reverse transcriptase inhibitor;
NTRI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
https://doi.org/10.1371/journal.pmed.1003421.t001
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RNA < 100 copies/ml throughout 48 weeks in the ITT population (risk difference −1.2%; 95%
CI −7.8% to 5.6%; non-inferiority margin −12%) (Table 2; Fig 2A). PP analysis showed similar
results, with 96.5% of patients maintaining viral suppression in both arms (treatment differ-
ence 0.0%; 95% CI −5.6% to 5.5%) (Table 2). There was no relevant interaction between the
type of drug treatment and type of monitoring for the primary outcome (interaction ratio
0.98; 95% CI 0.85 to 1.13; p = 0.81). We did not observe any difference in efficacy by monitor-
ing arm (S1 Table). One patient (0.5%) in the cART arm on abacavir/3TC/DTG failed accord-
ing to the protocol virological failure definition, i.e., 2 consecutive HIV-1 RNA values� 100
copies/ml. Five patients presented with a single HIV-1 RNA� 200 copies at least once during
the 48-week follow-up, followed by an undetectable viral load, and were not considered as true
virological failures.
Table 2. Proportions of patients with HIV-1 RNA< 100 copies/ml throughout 48 weeks.
Outcome DTG + FTC cART Difference (95% CI) Non-inferiority met?�
ITT analysis n = 93 n = 94
HIV-1 RNA < 100 copies/ml throughout 48 weeks (±21 days) 93.5% (87) 94.7% (89) −1.2% (−7.8% to +5.6%) Yes
PP analysis n = 85 n = 86
HIV-1 RNA < 100 copies/ml throughout 48 weeks (±21 days) 96.5% (82) 96.5% (83) −0.0% (−5.6% to +5.5%) Yes
Mantel–Haenszel risk difference with 95% confidence intervals for the ITT and PP analysis.
�Non-inferiority-margin: −12%.
cART, combined antiretroviral therapy; CI, confidence interval; DTG, dolutegravir; FTC, emtricitabine; ITT, intention-to-treat; PP, per-protocol.
https://doi.org/10.1371/journal.pmed.1003421.t002
Fig 2. Virological outcomes at week 48. Adjusted treatment difference for the primary outcome (A) and the FDA
snapshot analysis (B) and virological response in the ITT population by the FDA snapshot algorithm (C). AE, adverse
event; cART, combined antiretroviral therapy; CI, confidence interval; DTG, dolutegravir; FDA, US Food and Drug
Administration; FTC, emtricitabine; ITT, intention-to-treat; LTFU, lost to follow-up.
https://doi.org/10.1371/journal.pmed.1003421.g002
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Secondary outcomes
Using the FDA snapshot algorithm, 84/93 (90.3%) participants in the DTG + FTC arm had
HIV-1 RNA < 50 copies/ml at week 48, compared to 86/94 (91.5%) in the standard cART arm
(risk difference −1.1%; 95% CI −9.3% to 7.1%; p = 0.791) (Fig 2B and 2C). Two patients, 1 in
each arm, had HIV-1 RNA� 50 copies/ml at week 48. These patients did not overlap with the
participant who virologically failed according to the primary endpoint. For 5 additional
patients, week 48 HIV-1 RNA measurements were available but were outside the window
period of ±21 days (S2 Table). Adherence through 48 week reached 98.6% in the DTG + FTC
arm and 98.7% in the cART arm (risk difference +0.2%; 95% CI −0.9% to 1.4%; p = 0.671).
We did not observe any new occurrence of resistance, and thus no loss of future drug
options, among patients who virologically failed according to the primary or secondary out-
come. Of note, we did not detect DTG plasma levels for the patient who experienced virologi-
cal failure according to the primary outcome. Still, 41L and 69D thymidine analogue
mutations were present at the time of virological failure. These mutations were transmitted as
they were observed in the genotyping performed at the time of HIV diagnosis, before any
exposure to HIV treatment. Overall, no patient required a change of therapy, although 1
patient in the DTG + FTC arm requested to switch back to standard cART due to low-level
viremia occurring before week 48. As we only observed 1 virological failure, we were not able
to explore risk factors for this outcome.
Adverse effects
The most commonly reported adverse events across both treatment arms were upper respira-
tory infection (20.9%), headache (10.2%), diarrhea (7%), and insomnia (4.3%) (Table 3). The
proportion of patients with serious adverse events was higher in the cART arm (16%) com-
pared to the DTG + FTC arm (6.5%) (risk difference −9.5%; 95% CI −18.2% to −0.4%;
p = 0.041). None of the serious adverse events was considered to be related to the study medi-
cation. There was no difference in the proportion of participants with serious adverse events
by monitoring arm (10.5% in the PCM arm versus 12% in the SM arm; risk difference −1.3%
(95% CI −10.2% to +7.7%; p = 0.781) (S3 Table). One participant in each arm (1%) had an
adverse event leading to discontinuation of the study drug (suicidal ideation in the DTG +
Table 3. Summary of reported adverse events.
Adverse event outcome DTG + FTC (n = 93) cART (n = 94)
At least 1 adverse event, n (%) 65 (69.9) 57 (60.6)
Upper respiratory infection 20 (21.5) 19 (20.2)
Diarrhea 12 (12.9) 1 (1.1)
Headache 10 (10.8) 9 (9.6)
Insomnia 6 (6.5) 2 (2.1)
Fever 4 (4.3) 5 (5.3)
Myalgia 4 (4.3) 2 (2.1)
Rash 3 (3.2) 6 (6.4)
At least 1 serious adverse event, n (%) 6 (6.5) 15 (16)
Adverse event leading to withdrawal from the intervention, n (%) 1 (1.1) 1 (1.1)
Adverse event leading to withdrawal from the study, n (%) 0 0
cART, combined antiretroviral therapy; DTG, dolutegravir; FTC, emtricitabine.
https://doi.org/10.1371/journal.pmed.1003421.t003
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FTC arm and arthralgia in the cART arm). No participant became pregnant during the study.
The full list of the reported serious adverse events is presented in S4 Table.
We observed no difference in the change in CD4 count or lipid profile from baseline to
week 48 between the treatment arms. Creatinine clearance was significantly lower in the
DTG + FTC arm compared to the cART arm (adjusted difference −4.3 ml/min/1.73 m2; 95%
CI −7.3 to −1.3; p = 0.006). We observed a slight increase in weight in both arms, but without a
statistically significant difference between the arms. Changes between baseline and week 48 in
safety endpoints are presented in Table 4.
Patient-reported outcomes
Mean scores for QoL at baseline and week 48 were high in both treatment arms as measured
by the PROQOL-HIV questionnaire. The PROQOL score was rated above 80/100 points for
all participants at week 48. Change in QoL between baseline and week 48 with this measure
was statistically superior in the DTG + FTC arm (+2.9 points) compared to the cART arm
(+0.3 points) (adjusted difference +2.6, 95% CI +0.4 to +4.7; p = 0.023) (Table 5). We observed
no significant difference in change in QoL in patients randomized in the PCM arm (+2.2
points) compared to the SM arm (+1 point) (adjusted difference +1.6; 95% CI −0.6 to 3.8;
p = 0.166).
At study termination, patients were offered the choice of remaining on their allocated treat-
ment or switching to another regimen; 85.6% of patients in the dual therapy arm decided to
stay on the dual combination of DTG + FTC, whereas 32.2% of participants in the cART
decided to initiate DTG + FTC.
Table 4. Changes in safety endpoints between baseline and week 48.
Safety endpoint Mean (±SD) change between baseline and
week 48
Adjusted difference (95% CI) p-Value
DTG + FTC (n = 93) cART (n = 94)
CD4 cell count, cells/mm3 +10.8 (±174.4) −9.4 (±156.6) +23.1 (−24.0; +70.2) 0.334
Total cholesterol, mmol/l −0.24 (±0.63) −0.13 (±0.69) −0.06 (−0.24; +0.11) 0.484
LDL-cholesterol, mmol/l −0.16 (±0.57) +0.01 (±0.59) −0.14 (−0.30; +0.02) 0.095
Triglycerides, mmol/l −0.11 (±0.92) −0.14 (±0.78) −0.00 (−0.21; +0.22) 0.983
Estimated creatinine clearance (CKD-EPI), ml/min/1.73 m2 −2.4 (±11.8) +1.1 (±9.5) −4.3 (−7.3; −1.3) 0.006
Weight, kg +1.3 (±3.3) +0.3 (±3.6) +1.0 (−0.0; +2.0) 0.058
Glucose profile in mmol/l −0.2 (±1.2) +0.1 (±1.2) −0.3 (−0.6; −0.0) 0.047
Framingham-calculated cardiovascular risk +0.1 (±2.5) +0.4 (±2.6) −0.3 (−1.0; +0.4) 0.434
cART, combined antiretroviral therapy; CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DTG, dolutegravir; FTC,
emtricitabine; LDL, low-density lipoprotein.
https://doi.org/10.1371/journal.pmed.1003421.t004
Table 5. Summary of patients’ quality of life scores by treatment arm.
Outcome measure Mean (±SD) change; n Adjusted difference (95%CI) p-Value
DTG + FTC (n = 93) cART (n = 94)
Change in QoL between baseline and week 12 (PROQOL-HIV questionnaire) +2.3 (±6.7); n = 79 +0.2 (±7.0); n = 79 +2.1 (+0.1; +4.1) 0.041
Change in QoL between baseline and week 48 (PROQOL-HIV questionnaire) +2.9 (±6.7); n = 80 +0.3 (±8.6); n = 85 +2.6 (+0.4; +4.7) 0.023
cART, combined antiretroviral therapy; DTG, dolutegravir; FTC, emtricitabine; QoL, quality of life.
https://doi.org/10.1371/journal.pmed.1003421.t005
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Discussion
SIMPL’HIV, a nationwide randomized trial in Switzerland, tested FTC in combination with
DTG as a 2-drug regimen. Switching HIV-1-infected virologically suppressed participants to
DTG + FTC was non-inferior in terms of efficacy compared to maintaining standard cART
through a duration of 48 weeks. ITT analysis showed that the percentage of patients maintain-
ing viral suppression (<100 copies/ml) through 48 weeks was 93.5% in the DTG + FTC arm
and 94.7% in the cART arm, thus confirming non-inferiority of the 2-drug arm. We demon-
strated a good safety profile of the dual therapy, with few serious adverse events, 6.5% of
patients in the DTG + FTC arm and 16% in the cART arm. None was drug-related. QoL
improved more between baseline and week 48 in the DTG + FTC arm compared to the cART
arm, while there was no difference in QoL over time in the PCM arm compared to the SM
one. The lack of improvement in QoL whatever the monitoring arm might reflect the already
facilitated access to care in Switzerland and the high level of trust by patients in the healthcare
system.
The FDA snapshot virological outcome, with 90.3% of patients having virological suppres-
sion in the DTG + FTC arm versus 91.5% in the cART arm, also met the non-inferiority crite-
rion. Our results are similar to those of the TANGO trial, in which 93.2% of patients had
virological suppression in the DTG/3TC arm versus 93% in the standard ART arm [8], and the
SWORD studies, in which virological suppression was achieved in 95% of participants in both
the DTG/rilpivirine and control arms at week 48 [35]. However, the SIMPL’HIV study had
fewer eligibility constraints compared to these trials. We had no restriction in the comparator
cART arm as long as the treatment followed EACS guidelines. The TANGO trial recruited
patients on a tenofovir alafenamide fumarate (TAF)–based regimen, and the SWORD studies
included participants on 2 NRTIs plus a third agent, preferably not DTG, before any switch
[8,35]. Furthermore, we included patients independent of US Centers for Disease Control and
Prevention clinical stage, nadir CD4 count, or HIV-1 zenith viral load values. Indeed, median
nadir CD4 count for our participants was quite low (246 cells/mm3 [IQR 147–340]), thus
reflecting routine urban HIV care.
The safety profile of DTG + FTC was consistent with the safety profiles of DTG/3TC and
DTG/rilpivirine in the TANGO and SWORD trials, respectively. We observed a significantly
lower estimated creatinine clearance in the DTG + FTC compared to the cART arm. DTG is
known to increase serum creatinine and reduce creatinine clearance by inhibiting the tubular
secretion of creatinine [36]. However, we did not measure cystatin C level and therefore can-
not judge if this finding is clinically relevant. Similarly to TANGO and SWORD, weight
slightly increased in both treatment arms, but the difference between arms was not significant
[8,35].
Our novel viral suppression outcome, defined as HIV-1 RNA < 100 copies/ml through 48
weeks’ duration, allowed us to observe the occurrence of blips in both treatment arms, with no
consequences for HIV management. However, we did not assess inflammatory parameters,
which may be affected in the context of continuous antigen exposure. SIMPL’HIV addressed
treatment optimization not only by assessing a 2-drug maintenance regimen, but also by sim-
plifying HIV-1 monitoring through reducing the frequency of immunological and safety mea-
surements and providing patient-friendly approaches for follow-up. Treatment optimization
cannot only be driven by changes or modulations of antiretroviral drugs; drug and care deliv-
ery, including the frequency of laboratory tests, contribute to patient satisfaction and cost con-
trol. To our knowledge, no study has assessed such management optimization in a high-
income country.
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Our study has some limitations. First, despite our efforts to include women in a similar pro-
portion to our national prospective SHCS cohort, i.e., 28%, we failed to reach this target. A
qualitative study is planned to understand barriers—a possible implicit sex bias in research
both from the researcher side and from the participant side—to the participation of women in
clinical trials in Switzerland. Second, the open-label design may have introduced bias regard-
ing the reporting of adverse events. Such bias may explain the lower number of serious adverse
events observed in the DTG + FTC arm, because all participants were stable on standard cART
for nearly a decade before the start of the study, and such a difference was not expected.
Finally, our study duration of 48 weeks was short, and a longer follow-up is needed to docu-
ment the durability of DTG + FTC dual therapy in terms of efficacy and safety. All study
participants will be followed over an extended 3-year period to assess these issues.
The only virological failure occurred in a patient who had transmitted thymidine analogue
mutations at the time of HIV-1 diagnosis, before any exposure to antiretroviral drugs. Thus,
the results from resistance tests, as well as a detailed medical history, should be considered
before switching to a simplified therapy. Of note, this patient was randomized to cART, and
we did not detect any drug plasma concentration at the time of virological failure. Importantly,
no patient lost drug options during the course of the study.
In conclusion, this study provides evidence that the combination of DTG + FTC expands
the possibility of offering 2-drug simplification in maintenance treatment, especially as both
drugs are available as generic formulations. The combination demonstrated non-inferiority in
efficacy and safety, as well as a greater improvement in QoL over time compared to standard
regimens. An ongoing assessment of data from the SIMPL’HIV study regarding healthcare-
related costs and patient choices and satisfaction will provide additional insights into potential
advantages of dual therapy and PCM.
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